최소 단어 이상 선택하여야 합니다.
최대 10 단어까지만 선택 가능합니다.
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기대한방사선종양학회지 = The Journal of the Korean soceity for therapeutic radiology and oncology, v.20 no.4, 2002년, pp.328 - 333
김용배 (연세대학교 의과대학 연세암센터 방사선종양학교실) , 성진실 (연세대학교 의과대학 연세암센터 방사선종양학교실) , 송시영 (연세대학교 의과대학 연세암센터 내과학교실, Brain Korea 21 의과학사업단) , 박승우 (연세대학교 의과대학 연세암센터 내과학교실, Brain Korea 21 의과학사업단) , 서창옥 (연세대학교 의과대학 연세암센터 방사선종양학교실)
Purpose : To analyze the treatment results of concurrent chemoradiation with oral 5-FU plus Gemcitabine or Paclitaxel for unresectable pancreatic cancer. Materials & Methods : The patients, who were diagnosed by imaging modalities or by explo-laparotomy, were treated with concurrent chemoradiation. ...
* AI 자동 식별 결과로 적합하지 않은 문장이 있을 수 있으니, 이용에 유의하시기 바랍니다.
CentraI Cancer Registry Center, Ministry of HeaIth and WeIfare, Korea. Annnal report of the central cancer registry in Korea. 2000
Merrick III HW, DobeIbower RR. Aggressive therapy for cancer of the pancreas-dose it help? Gastroenterol CIin North Am 1990;19:935-962
Lee SJ, Lee YC, Song SY, et aI. Clinical study on pancreatic cancer and its prognostic factors. Korean J Gastroenterol 1994;26:1010-1020
Whang YW, Chang HJ, Lee JK, et aI. Survival and recurrence pattern after cfter curative resection of pancreatic cancer. Korean J Gastroenterol 2001;38:276-283
MoerteI CG, ChiIds DS, Reitemeier RJ, CoIby MY, HoIbrook MA. Combined 5-fluorouraciI and supervoltage radiation therapy of locally unresectabIe gasrointestinal cancer. Lancet 1969;2:865-867
MoerteI CG, Frytak S, Hahn RG, et aI. Therapy of Iocally unreaectabIe pancreatic carcinoma : A randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads+5-fluorouracil), and high dose radiation+5-fluorouracil : The Gastrointestinal Tumor Study Group. Cancer 1981;48:1705-1710
Lawrence TS, Eisbruch A, Shewach DS. Gemcitabinemediated radiosensitization. Semin Oncol 1997;24(2, S7):24-28
Hak C, Rodriguez FF, Koester S, HiIsenbeck S, Von Hoff D. Investigation of Taxol as a potential radiation sensitizer. Cancer 1993;71:3774-8
BIackstock AW, Bernard SA, Richards F, et aI. Phase I trial of twice-weekly gemcitabine and concurrent radiation in patients with advanced pancreatic cancer. J Clin Oncol 1999;17:2208-2212
Kudrimoti M, Regine W, John W, et aI. Concurrent infusional gemcitabine and radiation in the treatment of advanced unresectabIe GI maIignancy : A phase I/II study. Proc Am Soc Clin Oncol 1999;28:242a
Wong S, Oza AM, BrierIey J, et aI. Phase I study of gemcitabine and escaIating dose radiation therapy in patients with pancreatic carcinoma. Proc Am Soc CIin Oncol 2000;19:268a
MiIas L, Fujii T, Hunter NR, et aI. Enhancement of tumor radioresponse in vivo by gemcitabine. Cancer Res 1999;59:107-114
Lawrence TS, Chang EY, HerteI L, et aI. Gemcitabine radiosensitizes human pancreatic cancer cells. Proc Am Assoc Cancer Res 1994;35:647
Huang NJ, HitteIman WN. Transient inhibition of chromosome damage repair after after ionizing radiation by gemcitabine. Proc Am Assoc Cancer Res 1995;36:612
Mason KA, MiIas L, Hunter NR, et aI. Maximizing therapeutic gain with gemcitabine and fractionated radiation. Int J Radiat Oncol Biol Phys 1999;44:1125-1135
WoIff R, Janjan N, Lenzi R, et aI. Treatment related toxicities with rapid-fractionation external beam radiation and concomitant gemcitabine for Iocally advanced nonmetastatic adenocarcinoma of the pancreas. Int J Radiat Oncol Biol Phys 1998;42:201
EpeIbaum R, RosenbIatt E, NasraIIah S, et aI. Phase II study of gemcitabine pancreatic cancer. Eur J Cancer 1999;35:S148-149
Abad A, AreIIano A, Brunet J, et aI. Gemcitabine plus radiotherapy in stage II-III pancreatic cancer : A phase I trial. Ann Oncol 1998;9:53
McGinn CJ, ZaIupski MM, Shureiqi I, et aI. Phase I Trial of radiation dose escalation with concurrent weekly full-dose gemcitabine in patients with advanced pancreatic cancer. J CIin Oncol 2001;19:4102-4208
Hoffman JP, McGinn CJ, Ross E, et aI. A Phase I Trial of preoperative gemcitabine for patients with locaIized,resectabIe pancreatic adenocarcinoma. Cancer Invest 1999;17:30-32
Safran H, King TP, Choy H, et aI. Paclitaxel and concurrent radiation for Iocally advanced pancreatic and gastric cancer : a phase I study. J CIin Oncol 1997;15:901-907
Safran H, Moore T, Iannitti D, et aI. Paclitaxel and concurrent radiation for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 2001;49:1275-1279
Rowinsky EK, WindIe JJ, Von Hoff DD. Ras protein farnesyltransferase : a strategic target for anticancer therapeutic development. J CIin Oncol 1999;17:3631
※ AI-Helper는 부적절한 답변을 할 수 있습니다.